SE9301830D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9301830D0
SE9301830D0 SE19939301830A SE9301830A SE9301830D0 SE 9301830 D0 SE9301830 D0 SE 9301830D0 SE 19939301830 A SE19939301830 A SE 19939301830A SE 9301830 A SE9301830 A SE 9301830A SE 9301830 D0 SE9301830 D0 SE 9301830D0
Authority
SE
Sweden
Prior art keywords
new compounds
improved
omeprazole
enantiomer
manufacture
Prior art date
Application number
SE19939301830A
Other languages
English (en)
Swedish (sv)
Inventor
Lennart *Lindberg Per
P O *Von Unge Sverker
Original Assignee
Ab Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9301830(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ab Astra filed Critical Ab Astra
Priority to SE19939301830A priority Critical patent/SE9301830D0/xx
Publication of SE9301830D0 publication Critical patent/SE9301830D0/xx
Priority to IS4161A priority patent/IS1854B/is
Priority to TW083104255A priority patent/TW389761B/zh
Priority to HR940307A priority patent/HRP940307B1/xx
Priority to LTIP1941A priority patent/LT3287B/lt
Priority to IL10968494A priority patent/IL109684A/en
Priority to ZA943557A priority patent/ZA943557B/xx
Priority to DZ940055A priority patent/DZ1785A1/fr
Priority to MA23521A priority patent/MA23210A1/fr
Priority to PT94917244T priority patent/PT652872E/pt
Priority to PL94307261A priority patent/PL178994B1/pl
Priority to ES00108480.5T priority patent/ES2326405T5/es
Priority to AT94917244T priority patent/ATE197452T1/de
Priority to ES00108479T priority patent/ES2326404T3/es
Priority to HU9500247A priority patent/HU226824B1/hu
Priority to YU31494A priority patent/YU49065B/sh
Priority to SK101-95A priority patent/SK282524B6/sk
Priority to DK00108479T priority patent/DK1020460T3/da
Priority to EP94917244A priority patent/EP0652872B1/en
Priority to JP50055395A priority patent/JP3549111B2/ja
Priority to PT00108479T priority patent/PT1020460E/pt
Priority to NZ266915A priority patent/NZ266915A/en
Priority to AU69024/94A priority patent/AU676337C/en
Priority to CZ1995202A priority patent/CZ287876B6/cs
Priority to UA95018075A priority patent/UA60289C2/uk
Priority to CN94190335A priority patent/CN1055469C/zh
Priority to EP00108480.5A priority patent/EP1020461B2/en
Priority to DE69435220T priority patent/DE69435220D1/de
Priority to MYPI94001349A priority patent/MY121192A/en
Priority to SI9420002A priority patent/SI9420002B/sl
Priority to PT00108480T priority patent/PT1020461E/pt
Priority to CA002139653A priority patent/CA2139653C/en
Priority to KR1019950700365A priority patent/KR100337274B1/ko
Priority to TNTNSN94058A priority patent/TNSN94058A1/fr
Priority to US08/256,174 priority patent/US5693818A/en
Priority to ES94917244T priority patent/ES2099047T3/es
Priority to DE69435221T priority patent/DE69435221D1/de
Priority to CA002337581A priority patent/CA2337581A1/en
Priority to DK00108480.5T priority patent/DK1020461T4/en
Priority to DE69426254T priority patent/DE69426254T2/de
Priority to SI9420085A priority patent/SI22752B/sl
Priority to DK94917244T priority patent/DK0652872T3/da
Priority to EP00108479A priority patent/EP1020460B1/en
Priority to PCT/SE1994/000509 priority patent/WO1994027988A1/en
Priority to DE0652872T priority patent/DE652872T1/de
Priority to RU95105587A priority patent/RU2137766C1/ru
Priority to SG1996008770A priority patent/SG49283A1/en
Priority to SA94140756A priority patent/SA94140756B1/ar
Priority to SA05260103A priority patent/SA05260103B1/ar
Priority to EE9400363A priority patent/EE03157B1/xx
Priority to LVP-94-266A priority patent/LV11034B/en
Priority to US08/376,512 priority patent/US5714504A/en
Priority to NO950263A priority patent/NO307378B1/no
Priority to FI950377A priority patent/FI117755B/fi
Priority to US08/833,962 priority patent/US5877192A/en
Priority to GR970300012T priority patent/GR970300012T1/el
Priority to HK98109228A priority patent/HK1008330A1/xx
Priority to CN99118539A priority patent/CN1107503C/zh
Priority to US09/419,456 priority patent/US6143771A/en
Priority to US09/690,044 priority patent/US6875872B1/en
Priority to HK00107518.8A priority patent/HK1028044A1/xx
Priority to HK00107520.4A priority patent/HK1028045A1/xx
Priority to GR20010400191T priority patent/GR3035365T3/el
Priority to CY0100010A priority patent/CY2224B1/xx
Priority to JP2003317637A priority patent/JP3959056B2/ja
Priority to JP2003317639A priority patent/JP4039999B2/ja
Priority to US11/002,982 priority patent/US20060004057A1/en
Priority to FI20070002A priority patent/FI20070002A/fi
Priority to US11/679,264 priority patent/US20080312449A1/en
Priority to CL2009000805A priority patent/CL2009000805A1/es
Priority to US12/551,828 priority patent/US20100222591A1/en
Priority to NO2011009C priority patent/NO2011009I1/no
Priority to LU91870C priority patent/LU91870I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
SE19939301830A 1993-05-28 1993-05-28 New compounds SE9301830D0 (sv)

Priority Applications (73)

Application Number Priority Date Filing Date Title
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds
IS4161A IS1854B (is) 1993-05-28 1994-05-06 Aðferð til að útbúa ljósfræðilega hrein Na+, Mg2+, Li+, K+ eða Ca2+ sölt (-)-5-metoxý-2-[[(4-metoxý-3,5-dímetýl-2-pýridínýl)metýl]súlfinýl]-1H-bensimídasóls og milliefnasamband.
TW083104255A TW389761B (en) 1993-05-28 1994-05-11 Omeprazole and its alkaline salts with high optically purity, their pharmaceutical compositions, process for preparation including their intermediates and application in pharmaceuticals
HR940307A HRP940307B1 (en) 1993-05-28 1994-05-17 New compounds
LTIP1941A LT3287B (en) 1993-05-28 1994-05-18 Optical pure compounds, a process for their preparation and their use
IL10968494A IL109684A (en) 1993-05-28 1994-05-19 Optically pure crystalline salts of the (-) - an enantiomer of omeprazole, a process for their preparation and pharmaceutical preparations containing them
ZA943557A ZA943557B (en) 1993-05-28 1994-05-23 Highly optical pure benzimidazoles and salts thereof
DZ940055A DZ1785A1 (fr) 1993-05-28 1994-05-25 Nouveaux composés.
MA23521A MA23210A1 (fr) 1993-05-28 1994-05-26 Nouveaux composes
PT94917244T PT652872E (pt) 1993-05-28 1994-05-27 Sal de magnesio do composto piridinil metil sulfinil-1h-benzimidazole opticamente puro
PL94307261A PL178994B1 (pl) 1993-05-28 1994-05-27 Optycznie czyste sole zwiazków pirydynylometylosulfinylo-1H-benzimidazolu i srodek farmaceutyczny je zawierajacy PL PL PL PL PL PL PL
ES00108480.5T ES2326405T5 (es) 1993-05-28 1994-05-27 Sal de magnesio del enantiómero(-) del omeprazol y su uso
AT94917244T ATE197452T1 (de) 1993-05-28 1994-05-27 Optisch reines magnesium-salz eines pyridinylmethylsulfinyl-1h-benzimidazole-deriva s
ES00108479T ES2326404T3 (es) 1993-05-28 1994-05-27 Sal sodica del enantiomero (-) de omeprazol.
HU9500247A HU226824B1 (en) 1993-05-28 1994-05-27 Optically active salts of pyridinyl-methyl-sulfinyl-1h-benzimidazol derivatives, pharmaceutical compositions containing them and process for producing them
YU31494A YU49065B (sh) 1993-05-28 1994-05-27 Omeprazol enantiomeri, postupak za njihovo dobijanje, farmaceutski proizvodi i njihova upotreba u medicini
SK101-95A SK282524B6 (sk) 1993-05-28 1994-05-27 Opticky čisté soli (-)-enantioméru pyridylmetylsulfinyl-1H- benzimidazolových zlúčenín, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty na ich prípravu
DK00108479T DK1020460T3 (da) 1993-05-28 1994-05-27 Natriumsalt af (-)enantiomeren af omeprazol
EP94917244A EP0652872B1 (en) 1993-05-28 1994-05-27 Optically pure magnesium -salt of pyridinylmethyl sulfinyl-1h-benzimidazole compound
JP50055395A JP3549111B2 (ja) 1993-05-28 1994-05-27 新規な化合物
PT00108479T PT1020460E (pt) 1993-05-28 1994-05-27 Sal de sódio do enantiómero (-) de omeprazole
NZ266915A NZ266915A (en) 1993-05-28 1994-05-27 Optically pure salts of (+)- and (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl] -sulphinyl]-1h-benzimidazole; pharmaceutical compositions (omeprazole)
AU69024/94A AU676337C (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-IH- benzimidazole compounds
CZ1995202A CZ287876B6 (cs) 1993-05-28 1994-05-27 Opticky čistý pyridylmethylsulfinyl-1H-benzimidazolový derivát, způsob jeho výroby, farmaceutický prostředek s jeho obsahem a meziprodukt pro jeho výrobu
UA95018075A UA60289C2 (uk) 1993-05-28 1994-05-27 Оптично чисті солі (-)-5-метокси-2-[[(4-метокси-3,5-диметил-2-піридиніл)метил]сульфініл]-1h-бензімідазолу, спосіб їх одержання, проміжні сполуки та фармацевтична композиція
CN94190335A CN1055469C (zh) 1993-05-28 1994-05-27 旋光纯的吡啶甲基亚磺酰基－1h－苯并咪唑类化合物的盐、及其制法和应用
EP00108480.5A EP1020461B2 (en) 1993-05-28 1994-05-27 Magnesium salt of the (-)-enantiomer of omeprazole and its use
DE69435220T DE69435220D1 (de) 1993-05-28 1994-05-27 Das Natrium Salz des (-)-Enantiomer von Omeprazole
MYPI94001349A MY121192A (en) 1993-05-28 1994-05-27 New compounds.
SI9420002A SI9420002B (sl) 1993-05-28 1994-05-27 Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin
PT00108480T PT1020461E (pt) 1993-05-28 1994-05-27 Sal de magnésio do enantiómero (-) de omeprazole
CA002139653A CA2139653C (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-ih- benzimidazole compounds
KR1019950700365A KR100337274B1 (ko) 1993-05-28 1994-05-27 피리딘메틸술피닐-1h-벤즈이미다졸화합물의광학적으로순수한염
TNTNSN94058A TNSN94058A1 (fr) 1993-05-28 1994-05-27 Nouveaux composes
US08/256,174 US5693818A (en) 1993-05-28 1994-05-27 Process for preparing pure salts of pyridinylmethyl-sulfinyl-1H-benzimidazole
ES94917244T ES2099047T3 (es) 1993-05-28 1994-05-27 Sal de magnesio opticamente pura de un compuesto de piridinilmetilsulfinil-1h-bencimidazol.
DE69435221T DE69435221D1 (de) 1993-05-28 1994-05-27 Magnesiumsalz des (-)-Enantiomers von Omeprazol und dessen Verwendung
CA002337581A CA2337581A1 (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-1h-benzimidazole compounds and intermediates in the preparation therefor
DK00108480.5T DK1020461T4 (en) 1993-05-28 1994-05-27 The magnesium salt of the (-) enantiomer of omeprazole and the use of this
DE69426254T DE69426254T2 (de) 1993-05-28 1994-05-27 Optisch reines magnesium-salz eines pyridinylmethylsulfinyl-1h-benzimidazole-derivats
SI9420085A SI22752B (sl) 1993-05-28 1994-05-27 Optično čiste soli piridinilmetil sulfinil-1H-benzimidazolovih spojin
DK94917244T DK0652872T3 (da) 1993-05-28 1994-05-27 Optisk rent magnesiumsalt af pyridinylmethylsulfinyl-1H-benzimidazolforbindelse
EP00108479A EP1020460B1 (en) 1993-05-28 1994-05-27 The sodium salt of the (-)-enantiomer of omeprazole
PCT/SE1994/000509 WO1994027988A1 (en) 1993-05-28 1994-05-27 Optically pure salts of pyridinylmethyl sulfinyl-ih-benzimidazole compounds
DE0652872T DE652872T1 (de) 1993-05-28 1994-05-27 Optisch reine salze von pyridinylmethylsulfinyl-1h-benzimidazole-derivaten.
RU95105587A RU2137766C1 (ru) 1993-05-28 1994-05-27 Оптически чистые na+, mg2+, li+, k+ или са2+ соли (-)-5-метокси-2[[(4-метокси-3,5-диметил-2-пиридинил)метил] сульфинил]-1h-бензимидазола, способ их получения, фармкомпозиция на их основе и промежуточное соединение
SG1996008770A SG49283A1 (en) 1993-05-28 1994-05-27 New compounds
SA94140756A SA94140756B1 (ar) 1993-05-28 1994-06-04 ملح magnesium نقي ضوئياً لمركب pyridinylmethyl sulfinyl- 1H- benzimidazole
SA05260103A SA05260103B1 (ar) 1993-05-28 1994-06-04 ملح الصوديوم للمتشاكل -(-) للأومبرازول
EE9400363A EE03157B1 (et) 1993-05-28 1994-11-17 Omeprasooli enantiomeerid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid
LVP-94-266A LV11034B (en) 1993-05-28 1994-12-30 Optically pure salts of pyridinilmethyl sulfinyl-1h-benzimidazole compounds
US08/376,512 US5714504A (en) 1993-05-28 1995-01-23 Compositions
NO950263A NO307378B1 (no) 1993-05-28 1995-01-24 Optisk rene salter av pyridinylmetylsulfinyl-1H- benzimidazolforbindelser, fremgangsmåte for deres fremstilling, farmasøytisk preparat inneholdende slike forbindelser og deres anvendelse samt mellomprodukter
FI950377A FI117755B (fi) 1993-05-28 1995-01-27 Menetelmä pyridinyylimetyylisulfinyyli-1H-bentsimidatsoliyhdisteen terapeuttisesti aktiivisen, optisesti puhtaan natrium- tai magnesiumsuolan valmistamiseksi
US08/833,962 US5877192A (en) 1993-05-28 1997-04-11 Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
GR970300012T GR970300012T1 (en) 1993-05-28 1997-05-30 Optically pure salts of pyridinylmethyl sulfinyl-1h-benzimidazole compounds.
HK98109228A HK1008330A1 (en) 1993-05-28 1998-07-17 Optically pure magnesium-salt of pyridinylmethyl sulfinyl-1h-benzimidazole compound
CN99118539A CN1107503C (zh) 1993-05-28 1999-09-03 一种旋光纯化合物的药用
US09/419,456 US6143771A (en) 1993-05-28 1999-10-15 Compounds
US09/690,044 US6875872B1 (en) 1993-05-28 2000-10-16 Compounds
HK00107518.8A HK1028044A1 (en) 1993-05-28 2000-11-23 Magnesium salt of the (-)-enantiomer of omeprazole and its use
HK00107520.4A HK1028045A1 (en) 1993-05-28 2000-11-23 The sodium salt of the (-)-enantiomer of omeprazole
GR20010400191T GR3035365T3 (en) 1993-05-28 2001-02-05 Optically pure salts of pyridinylmethyl sulfinyl-1h-benzimidazole compounds.
CY0100010A CY2224B1 (en) 1993-05-28 2001-05-22 Optically pure salts of pyridinylmethyl sulfinyl-1H-benzimidazole compounds
JP2003317637A JP3959056B2 (ja) 1993-05-28 2003-09-10 新規な化合物
JP2003317639A JP4039999B2 (ja) 1993-05-28 2003-09-10 新規な化合物の製造方法
US11/002,982 US20060004057A1 (en) 1993-05-28 2004-12-01 New compounds
FI20070002A FI20070002A (fi) 1993-05-28 2007-01-02 Pyridinyylimetyylisulfinyyli-1H-bentsimidatsoliyhdisteiden optisesti puhtaat suolat
US11/679,264 US20080312449A1 (en) 1993-05-28 2007-02-27 New Compounds
CL2009000805A CL2009000805A1 (es) 1993-05-28 2009-04-02 Composicion farmaceutica que comprende a una sal sodica del enantiomero (-) de 5-metoxi-2[[(4-metoxi-3,5-dimetil-2-piridinil)metil]sulfinil]-1h-bencimidazol ((-)-omeprazol); y su uso en la inhibicion de la secrecion de acido gastrico y para tratar enfermedades inflamatorias gastrointestinales. (divisional solicitud 3570-00).
US12/551,828 US20100222591A1 (en) 1993-05-28 2009-09-01 New Compounds
NO2011009C NO2011009I1 (no) 1993-05-28 2011-06-07 Naproksen- og esomeprazoltabletter med modifisert frisetting
LU91870C LU91870I2 (fr) 1993-05-28 2011-09-19 Une combinaison de produit comprenant du naproxèneet un sel de magnésium d'esomeprazole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds

Publications (1)

Publication Number Publication Date
SE9301830D0 true SE9301830D0 (sv) 1993-05-28

Family

ID=20390088

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds

Country Status (43)

Country Link
US (5) US5693818A (xx)
EP (3) EP1020461B2 (xx)
JP (3) JP3549111B2 (xx)
KR (1) KR100337274B1 (xx)
CN (2) CN1055469C (xx)
AT (1) ATE197452T1 (xx)
CA (2) CA2337581A1 (xx)
CL (1) CL2009000805A1 (xx)
CY (1) CY2224B1 (xx)
CZ (1) CZ287876B6 (xx)
DE (4) DE69435220D1 (xx)
DK (3) DK1020461T4 (xx)
DZ (1) DZ1785A1 (xx)
EE (1) EE03157B1 (xx)
ES (3) ES2326405T5 (xx)
FI (2) FI117755B (xx)
GR (2) GR970300012T1 (xx)
HK (3) HK1008330A1 (xx)
HR (1) HRP940307B1 (xx)
HU (1) HU226824B1 (xx)
IL (1) IL109684A (xx)
IS (1) IS1854B (xx)
LT (1) LT3287B (xx)
LU (1) LU91870I2 (xx)
LV (1) LV11034B (xx)
MA (1) MA23210A1 (xx)
MY (1) MY121192A (xx)
NO (2) NO307378B1 (xx)
NZ (1) NZ266915A (xx)
PL (1) PL178994B1 (xx)
PT (3) PT1020461E (xx)
RU (1) RU2137766C1 (xx)
SA (2) SA05260103B1 (xx)
SE (1) SE9301830D0 (xx)
SG (1) SG49283A1 (xx)
SI (2) SI9420002B (xx)
SK (1) SK282524B6 (xx)
TN (1) TNSN94058A1 (xx)
TW (1) TW389761B (xx)
UA (1) UA60289C2 (xx)
WO (1) WO1994027988A1 (xx)
YU (1) YU49065B (xx)
ZA (1) ZA943557B (xx)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
MX9600857A (es) 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO1999029299A1 (en) * 1997-12-08 1999-06-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel suppository form comprising an acid-labile active compound
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
CA2298823C (en) * 1998-04-20 2011-06-07 Eisai Co., Ltd. Stabilized composition comprising a benzimidazole type compound
HUP0103464A3 (en) 1998-08-10 2002-11-28 U S Government Represented By Prodrugs of proton pump inhibitors and pharmaceutical compositions containing them
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
IL142629A0 (en) 1998-11-18 2002-03-10 Astra Ab Improved chemical process and pharmaceutical formulation
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
EP1191948A2 (en) * 1999-06-11 2002-04-03 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
EP1595879A3 (en) * 1999-08-26 2010-01-27 aaiPharma Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
WO2001024780A2 (en) * 1999-10-01 2001-04-12 Natco Pharma Limited Soft gel capsule resistant to gastric juices
CA2387746C (en) * 1999-10-20 2010-06-29 Koji Ukai Methods for stabilizing benzimidazole-based compounds
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
CA2400953A1 (en) 2000-02-24 2001-08-30 Kopran Research Laboratories Limited Orally administrable acid stable anti-ulcer benzimidazole derivatives
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
CA2409258A1 (en) * 2000-05-15 2001-11-22 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
AU2003204233B8 (en) * 2000-08-04 2008-06-26 Bernard Charles Sherman Magnesium salt of S-omeprazole
US7271182B2 (en) 2000-08-04 2007-09-18 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and use thereof
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
JP2004536034A (ja) 2001-01-08 2004-12-02 ネオルクス コーポレイション 治療的および診断的化合物、組成物および方法
JP2004536049A (ja) * 2001-04-13 2004-12-02 アプシンターム・リミテッド・ライアビリティ・カンパニー スルフィンアミドおよびスルホキシドの製造方法
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
KR20040025677A (ko) 2001-09-18 2004-03-24 제리아 신야쿠 고교 가부시키 가이샤 벤즈이미다졸 유도체
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
ES2286408T3 (es) * 2002-03-05 2007-12-01 Astrazeneca Ab Sales de alquilamonio de omeprazol e esomeprazol.
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
US6894066B2 (en) * 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
BR0312802A (pt) * 2002-07-19 2005-04-19 Michael E Garst Pró-drogas de inibidores de bombas de próton
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
WO2004012659A2 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
US7612098B2 (en) 2002-08-30 2009-11-03 Dr. Reddy's Laboratories Limited Amorphous hydrous esomeprazole magnesium
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
EP2596792A1 (en) 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
EA200500673A1 (ru) * 2002-10-22 2005-12-29 Рэнбакси Лабораториз Лимитед Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
KR101169471B1 (ko) 2002-12-06 2012-07-30 니코메드 게엠베하 (ｓ)-판토프라졸의 제조 방법
BRPI0310118B1 (pt) 2002-12-06 2015-10-20 Altana Pharma Ag processo para a preparação de inibidores de bomba de próton (ppi) opticamente puro possuindo uma estrutura de sulfinila
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
EP1606279A1 (en) * 2003-02-28 2005-12-21 Ranbaxy Laboratories, Ltd. Polymorphs of s-omeprazole
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
WO2004099182A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Zinc salt of (s)-omeprazole
WO2004099181A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
CN1823058A (zh) * 2003-07-15 2006-08-23 阿勒根公司 制备质子泵抑制剂的异构纯前体药物的方法
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
SI1651217T1 (sl) * 2003-07-23 2008-08-31 Nycomed Gmbh Alkalne soli inhibitorjev protonske ÄŤrpalke
WO2005011637A1 (ja) * 2003-08-04 2005-02-10 Eisai Co., Ltd. 用時分散型製剤
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
WO2005027880A1 (en) * 2003-09-25 2005-03-31 Natco Pharma Limited Enteric soft gelatin capsule containing esomeprazole and method of preparation
WO2005072079A2 (en) 2003-09-26 2005-08-11 Alza Coporation Drug coating providing high drug loading and methods for providing the same
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
JP2007523163A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
AU2005216863A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
DK1740571T3 (da) 2004-04-28 2009-11-02 Hetero Drugs Ltd Fremgangsmåde til fremstilling af pyridinylmethyl-1H-benzimidazolforbindelser i enantiomerisk beriget form eller som enkelte enantiomerer
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
ATE456566T1 (de) 2004-05-28 2010-02-15 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
CN1972928A (zh) * 2004-06-24 2007-05-30 阿斯利康(瑞典)有限公司 制备用于制备依美拉唑钠盐的结晶修饰物的新方法
US20080249134A1 (en) * 2004-06-24 2008-10-09 Ursula Hohlneicher New Esomeprazole Sodium Salt Crystal Modification
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
KR100847635B1 (ko) * 2004-08-06 2008-07-21 에자이 알앤드디 매니지먼트 가부시키가이샤 벤즈이미다졸 유도체와 아민과의 염
CN1993350B (zh) 2004-08-06 2010-05-12 卫材R&D管理有限公司 苯并咪唑衍生物与胺形成的盐及其制备方法
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
EP1830822A1 (en) * 2004-12-24 2007-09-12 LEK Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
JP4837722B2 (ja) 2005-03-25 2011-12-14 リブゾン ファーマシューティカル グループ インク． 置換スルホキシド化合物、その調製方法、およびその使用方法
RU2007145207A (ru) * 2005-05-06 2009-06-20 Гленмарк Фармасьютикалз Лимитед (In) Стронциваемая соль эзомепразола, способ ее получения и содержащее ее фармацевтические композиции
WO2006121995A2 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7563812B2 (en) 2005-06-15 2009-07-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
KR100641534B1 (ko) * 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
CA2617248C (en) * 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
CA2631919A1 (en) 2005-12-05 2007-06-14 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
EP1973896B1 (en) * 2005-12-28 2009-04-15 Union Quimico-Farmaceutica, S.A. A process for the preparation of the (s)-enantiomer of omeprazole
US8063074B2 (en) * 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US20090197919A1 (en) * 2006-06-07 2009-08-06 Rolf Bergman Novel Method for Preparation of Ammonium Salts of Esomeprazole
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
MX2008016196A (es) 2006-07-05 2009-01-20 Lupin Ltd Proceso para la preparacion de enantiomeros opticamente puros u opticamente enriquecidos de compuestos de sulfoxido.
PL2046334T3 (pl) 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
WO2008036201A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
BRPI0718611A2 (pt) * 2006-11-13 2014-02-25 Takeda Pharmaceuticals North America Inc Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
EP2120956A4 (en) * 2007-01-19 2010-01-20 Takeda Pharmaceuticals North A METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS
WO2008092939A2 (en) * 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CA2678702A1 (en) 2007-02-21 2008-08-28 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
EP2152691B1 (en) * 2007-06-07 2011-11-23 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
ES2375515T3 (es) 2007-09-25 2012-03-01 Hetero Drugs Limited Procedimiento de preparación de esomeprazol enantiomericamente puro.
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
JP2011512416A (ja) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009145368A1 (en) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
WO2010058409A2 (en) 2008-11-18 2010-05-27 Hetero Research Foundation Optical purification of esomeprazole
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
CA2766524A1 (en) * 2009-06-25 2010-12-29 Pozen Inc. Method for treating a patient in need of aspirin therapy
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
EP2499125B1 (en) 2009-11-12 2016-01-27 Hetero Research Foundation Process for the resolution of omeprazole
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
EP2534144B1 (en) 2010-02-12 2014-09-03 Esteve Química, S.A. Preparation process of the sodium salt of Esomeprazole
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
KR101797936B1 (ko) 2010-09-10 2017-11-15 다케다 파마슈티칼스 유에스에이, 인코포레이티드 테오필린과 페북소스타트의 병용 치료 방법
CN102816149B (zh) * 2011-06-10 2015-05-13 上海汇伦生命科技有限公司 一种高对映选择性合成(s)-奥美拉唑及其盐的制备方法
CN102807561A (zh) * 2011-06-21 2012-12-05 寿光富康制药有限公司 S-奥美拉唑铝盐及其制备方法和应用
CN102850323A (zh) * 2011-06-30 2013-01-02 秦引林 一种埃索美拉唑钠的精制方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN104844577A (zh) * 2011-07-31 2015-08-19 连云港润众制药有限公司 埃索美拉唑镁的晶型
WO2013081566A1 (en) 2011-11-25 2013-06-06 Mahmut Bilgic A formulation comprising benzimidazole
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
CN103420978A (zh) * 2012-05-15 2013-12-04 上海医药工业研究院 一种苯并咪唑类化合物的镁盐的制备方法
CN102657622A (zh) * 2012-05-17 2012-09-12 康普药业股份有限公司 一种含有埃索美拉唑钠的冻干粉针剂的制备工艺
CN102964335B (zh) * 2012-11-13 2014-06-25 凌元敏 一种埃索美拉唑钠化合物及其制备方法和用途
CN103159737B (zh) * 2013-04-12 2014-03-19 四川省惠达药业有限公司 一种埃索美拉唑钠化合物及药物组合物
US20160256399A1 (en) 2013-11-04 2016-09-08 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
WO2015155281A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104045627A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种奥美拉唑纯化方法
CN104530003A (zh) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法
EP2980086B1 (en) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of esomeprazole (S)-binol complex
WO2016104668A1 (ja) 2014-12-26 2016-06-30 国立大学法人 東京大学 光学活性のプロトンポンプ阻害化合物の製造方法
ES2615637T3 (es) 2015-03-06 2017-06-07 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Procedimiento mejorado para la purificación óptica del esomeprazol
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN105924430A (zh) * 2016-06-27 2016-09-07 杭州富阳伟文环保科技有限公司 一种埃索美拉唑钠的精制方法
US10939686B2 (en) * 2017-04-11 2021-03-09 Mclaughlin Gormley King Company Sabadilla oil and uses thereof
CN108409714A (zh) * 2018-03-29 2018-08-17 成都通德药业有限公司 埃索美拉唑、埃索美拉唑盐及埃索美拉唑镁的制备方法
CA3146660A1 (en) * 2019-07-16 2021-01-21 Kindred Biosciences, Inc. Equine esomeprazole formulations and methods of use
US20220306593A1 (en) 2019-08-29 2022-09-29 Tokyo University Of Science Foundation Method for preparing enantiomer of sulfoxide compound, and system for preparing enantiomer
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4636085A (en) * 1982-03-16 1987-01-13 Mapro Inc. Apparatus for removing volatiles from plastic materials delivered to an extrusion or injection molding machine
SE8204879D0 (sv) * 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US4445708A (en) * 1983-05-09 1984-05-01 General Motors Corporation Energy absorbing steering column for vehicles
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
EP0695123A4 (en) * 1993-04-27 1996-09-11 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING GASTRICAL FAULTS USING OPTICALLY PURE PANTOPRAZOLS
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
MX9600857A (es) * 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound

Also Published As

Publication number Publication date
FI117755B (fi) 2007-02-15
AU6902494A (en) 1994-12-20
IS4161A (is) 1994-11-29
PL307261A1 (en) 1995-05-15
HK1028045A1 (en) 2001-02-02
HRP940307B1 (en) 2001-06-30
EP1020460A3 (en) 2003-10-15
CZ20295A3 (en) 1995-10-18
SI22752A (sl) 2009-10-31
CA2337581A1 (en) 1994-12-08
ES2326404T3 (es) 2009-10-09
CL2009000805A1 (es) 2009-08-21
ATE197452T1 (de) 2000-11-11
LV11034A (lv) 1996-02-20
DE652872T1 (de) 1997-09-04
FI950377A0 (fi) 1995-01-27
SK10195A3 (en) 1995-09-13
GR3035365T3 (en) 2001-05-31
EP0652872B1 (en) 2000-11-08
JP4039999B2 (ja) 2008-01-30
EE03157B1 (et) 1999-02-15
EP0652872A1 (en) 1995-05-17
HK1008330A1 (en) 1999-05-07
US5693818A (en) 1997-12-02
JPH07509499A (ja) 1995-10-19
DE69435221D1 (de) 2009-09-03
EP1020461A2 (en) 2000-07-19
CN1107503C (zh) 2003-05-07
CA2139653A1 (en) 1994-12-08
SI9420002B (sl) 2009-12-31
ES2326405T5 (es) 2016-02-15
IS1854B (is) 2003-02-21
PT1020461E (pt) 2009-07-29
ES2326405T3 (es) 2009-10-09
AU676337B2 (en) 1997-03-06
JP3549111B2 (ja) 2004-08-04
SG49283A1 (en) 1998-05-18
US20080312449A1 (en) 2008-12-18
KR950702553A (ko) 1995-07-29
NO307378B1 (no) 2000-03-27
DE69426254T2 (de) 2001-06-07
SA94140756B1 (ar) 2006-05-20
DK1020460T3 (da) 2009-08-10
CY2224B1 (en) 2003-04-18
YU49065B (sh) 2003-08-29
RU2137766C1 (ru) 1999-09-20
HU226824B1 (en) 2009-11-30
NZ266915A (en) 1996-10-28
PT1020460E (pt) 2009-07-29
GR970300012T1 (en) 1997-05-31
LU91870I2 (fr) 2011-11-21
NO2011009I1 (no) 2011-06-20
CN1259346A (zh) 2000-07-12
IL109684A (en) 2002-05-23
LTIP1941A (en) 1994-12-27
IL109684A0 (en) 1994-12-29
EP1020461B1 (en) 2009-07-22
US20100222591A1 (en) 2010-09-02
ZA943557B (en) 1995-04-11
DK1020461T4 (en) 2016-02-15
HU9500247D0 (en) 1995-03-28
KR100337274B1 (ko) 2003-12-31
ES2099047T1 (es) 1997-05-16
SK282524B6 (sk) 2002-10-08
UA60289C2 (uk) 2003-10-15
YU31494A (sh) 1997-05-28
EP1020461B2 (en) 2015-10-21
ES2099047T3 (es) 2001-03-01
EP1020460A2 (en) 2000-07-19
NO950263L (no) 1995-01-24
RU95105587A (ru) 1996-10-27
TW389761B (en) 2000-05-11
DZ1785A1 (fr) 2002-02-17
JP3959056B2 (ja) 2007-08-15
DE69435220D1 (de) 2009-09-03
WO1994027988A1 (en) 1994-12-08
FI950377A (fi) 1995-01-27
MY121192A (en) 2006-01-28
LT3287B (en) 1995-06-26
CN1110477A (zh) 1995-10-18
US6143771A (en) 2000-11-07
CA2139653C (en) 2001-07-10
FI20070002A (fi) 2007-01-02
SI9420002A (en) 1995-08-31
NO950263D0 (no) 1995-01-24
JP2004043493A (ja) 2004-02-12
HUT71888A (en) 1996-02-28
SA05260103B1 (ar) 2010-01-31
CZ287876B6 (cs) 2001-03-14
DE69426254D1 (de) 2000-12-14
MA23210A1 (fr) 1994-12-31
JP2004043494A (ja) 2004-02-12
US5714504A (en) 1998-02-03
DK0652872T3 (da) 2001-03-05
PT652872E (pt) 2001-04-30
LV11034B (en) 1996-10-20
PL178994B1 (pl) 2000-07-31
EP1020461A3 (en) 2006-10-04
TNSN94058A1 (fr) 1995-04-25
DK1020461T3 (da) 2009-08-10
SI22752B (sl) 2010-01-29
HK1028044A1 (en) 2001-02-02
EP1020460B1 (en) 2009-07-22
HRP940307A2 (en) 1996-12-31
CN1055469C (zh) 2000-08-16

Similar Documents

Publication Publication Date Title
SE9301830D0 (sv) New compounds
HK1005425A1 (en) Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis
HUP9904030A2 (hu) Tiagabin felhasználása pszichotikus rendellenességek kezelésére alkalmas gyógyszer előállítására
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis